FDA Advisory Committee Votes that the Benefits of Ardelyx’s XPHOZAH (tenapanor) Outweigh its Risks

(24/7 MARKET NEWS) – Ardelyx, Inc. (Nasdaq:ARDX) announced, yesterday evening, that an FDA advisory committee voted 9:4 in favor of XPHOZAH as a monotherapy and 10:2 in favor of XPHOZAH in combination with phosphate binders, as its benefits outweigh its risks for the control of Serum Phosphorus in adult patients with chronic kidney disease on dialysis.

Ardelyx is trading in this morning’s premarket at $2.07, up $0.85 (+69.67%), on over 6.5 million shares traded in the premarket.

Its 52-week range is $0.4902 to $1.92. Its next inflection point is the $5.00 level from two years ago.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.